<DOC>
	<DOCNO>NCT01535820</DOCNO>
	<brief_summary>The purpose study assess bioequivalence contraceptive hormone ORTHO EVRA patch apply without adhesive overlay .</brief_summary>
	<brief_title>The Effect Adhesive Overlay Delivery Contraceptive Hormones From ORTHO EVRA® Healthy Women</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( people know identity intervention ) , single-center , single-application , 2-way crossover study ( participant receive different intervention sequentially trial ) ORTHO EVRA without adhesive overlay . ORTHO EVRA combination transdermal ( skin ) contraceptive patch contain 6.00 mg progestin norelgestromin ( NGMN ) 0.75 mg estrogen , ethinyl estradiol ( EE ) . The participant randomly assign 1 2 possible treatment sequence ensure receive follow treatment , 1 period : - Treatment A : ORTHO EVRA patch apply buttock adhesive overlay apply transdermal contraceptive system ; - Treatment B : ORTHO EVRA patch apply buttock without overlay . The study consist screen phase ; open-label treatment phase consist 2 single-application 7-day treatment period ; end-of-study withdrawal assessment do upon completion 240-hour pharmacokinetic sample Day 11 Period 2 upon withdrawal . Pharmacokinetic evaluation explore drug absorb body , distribute within body , remove body time . The two treatment period separate washout period ( period receive treatment ) 21 day . During study , safety tolerability also assess . The total duration participation study individual approximately 2 month .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Signed informed consent Body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg 90 kg Must surgically sterile intact ovary , abstinent , , sexually active , practice effective method nonhormonal birth control ( eg , nonhormonal intrauterine device , doublebarrier method , male partner sterilization ) entry throughout study Completed last term pregnancy least 90 day admission study site History regular menstrual cycle ( occur every 25 35 day ) Must pregnant lactating Blood pressure 90 140 mmHg systolic ( inclusive ) , high 90 mmHg diastolic Hemoglobin equal 12.0 screen History smoking use nicotinecontaining substance Used steroid hormonal therapy within 30 day admission study Received Depo Provera® injection 6 month admission study History presence disorder commonly accept contraindication sex hormonal therapy History current clinically significant medical illness condition investigator considers exclude patient could interfere interpretation study result</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>ORTHO EVRA</keyword>
	<keyword>Contraceptive hormone</keyword>
	<keyword>Transdermal patch</keyword>
	<keyword>Progestin norelgestromin ( NGMN )</keyword>
	<keyword>Estrogen ethinyl estradiol ( EE )</keyword>
	<keyword>JNJ-93964</keyword>
	<keyword>JNJ-622206</keyword>
</DOC>